StockData

Hyperfine vs Profound Medical

HYPR and PROF side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HYPR and PROF compare

Hyperfine grew revenue faster over the last twelve months (80.0% versus 65.3% for Profound Medical).

Profound Medical keeps more of each dollar of sales as profit, with a net margin of −138% compared with −156% at Hyperfine.

Hyperfine scores higher on the StockData Score (8 against 5 for Profound Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHYPRPROF
Size and price
Market cap$75.4M–
Share price$0.711$7.85
Change, 1 year−30.9%31.1%
Change, 5 years−92.9%−35.6%
Beta (5Y)1.051.03
Employees102162
StockData Score
Total score8 (better)5
Valuation score2 (better)0
Growth score4 (better)3
Performance score1 (better)0
Health score12 (better)
Dividend score00
Valuation
P/S4.0×–
P/B2.4×–
FCF yield−37.0%–
Fair value$0.772–
Margin of safety7.8%–
Growth
Revenue growth (TTM)80.0% (better)65.3%
Revenue growth, 5Y average115% (better)17.1%
EPS growth, 5Y average–2.4%
Profitability
Gross margin52.6%73.9% (better)
Operating margin−168%−145% (better)
Net margin−156%−138% (better)
FCF margin−146%–
Return on equity−102%−87.0% (better)
Return on invested capital−403%−213% (better)
Financial health
Debt / equity0.420.11 (better)
Interest coverage–−105.8×
Current ratio5.10 (better)4.54
Altman Z-score−7.43–
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions20.6%45.2%
Held by insiders18.1%1.6%
Insider net buying, 12 months−$91.9K–
Short interest, % of float4.5%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.